{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:48:41Z","timestamp":1764841721770},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T00:00:00Z","timestamp":1369267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T00:00:00Z","timestamp":1369267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/leu.2013.159","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T06:40:19Z","timestamp":1369291219000},"page":"2410-2413","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia"],"prefix":"10.1038","volume":"27","author":[{"given":"Q","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L-P","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-Y","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-H","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-S","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-Y","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-Z","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-R","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-Y","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X-J","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,23]]},"reference":[{"key":"BFleu2013159_CR1","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu2013159_CR2","unstructured":"National Comprehensive Cancer Network clinical practice guidelines in oncology: chronic myelogenous leukemia version 2 2011. http:\/\/www.nccn.org\/NCCN Guidelines\u2122 & Clinical Resources\/(accessed 20 June 2011)."},{"key":"BFleu2013159_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292\u20132302.","journal-title":"Blood"},{"key":"BFleu2013159_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbmt.2010.07.023","volume":"17","author":"XJ Huang","year":"2010","unstructured":"Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for subjects with chronic myeloid leukemia. Biol Blood Marrow Transplant 2010; 17: 649\u2013656.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013159_CR5","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","volume":"117","author":"Q Jiang","year":"2011","unstructured":"Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for subjects with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117: 3032\u20133040.","journal-title":"Blood"},{"key":"BFleu2013159_CR6","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","volume":"119","author":"J Guilhot","year":"2012","unstructured":"Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012; 119: 5963\u20135971.","journal-title":"Blood"},{"key":"BFleu2013159_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4757-5654-8_24","volume-title":"Lifetime data: models in reliability and survival analysis","author":"JP Klein","year":"1996","unstructured":"Klein JP, Zhang MJ . Statistical challenges in comparing chemotherapy and bone marrow transplantation as a treatment for leukemia. In: Jewell, Kimber, Lee, Whitmore (eds). Lifetime data: models in reliability and survival analysis. Kluwer Academic Publishers: Boston, MA, 1996; pp 175\u2013185."},{"key":"BFleu2013159_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu2013159_CR9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114, Abstract # 1126.","journal-title":"Blood"},{"key":"BFleu2013159_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","volume":"117","author":"J Pavlu","year":"2011","unstructured":"Pavlu J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755\u2013763.","journal-title":"Blood"},{"key":"BFleu2013159_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","volume":"47","author":"J Radich","year":"2010","unstructured":"Radich J . Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010; 47: 354\u2013361.","journal-title":"Semin Hematol"},{"key":"BFleu2013159_CR12","unstructured":"National Marrow Donor ProgramDisease and transplant outcome data, NMDP-facilitated transplant outcomes. National Marrow Donor Program, 2004. Available from URL http:\/\/www.marrow.org\/MEDICAL\/diseaseoutcomedata.html(accessed 20 June 2011)."},{"key":"BFleu2013159_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","volume":"19","author":"M Robin","year":"2005","unstructured":"Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005; 19: 1613\u20131620.","journal-title":"Leukemia"},{"key":"BFleu2013159_CR14","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"BFleu2013159_CR15","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011; 118: 4541\u20134546.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013159","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:30:23Z","timestamp":1648740623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,23]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFleu2013159"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.159","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,23]]},"assertion":[{"value":"23 May 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a part-time employee of Celgene Corporation, Summit, NJ, USA. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}